Treatment for<unk>  should focus primarily on reducing serum triglyceride levels. If an individual has co-morbid conditions, ensuring that they are adequately addressed will aid in obtaining a more normal baseline lipid panel. Current guidelines suggest that when evaluating individuals with<unk>  there should be special attention paid to their risk of developing cardiovascular disease in individuals with mild to moderate<unk> . Individuals with severe<unk>  should be promptly evaluated for the possibility of developing pancreatitis. The initial treatment for severe<unk>  consists of beginning an individual on fibrate therapy in an attempt to normalize triglyceride levels. Fibrates such as fenofibrate or gemfibrozil are considered first-line therapy for the disease. Adjunctive niacin therapy can be used for individuals who are unable to decrease triglyceride levels through fibrate monotherapy. Niacin is especially useful for individuals who have a high risk of getting pancreatitis. Fish oil supplement can also be used as it has been shown to incur a significant reduction to both triglyceride and VLDL levels. If properly managed, individuals with<unk>  have a fairly good prognosis. If therapy is successful, these individuals do not have uncontrolled severe triglycerides and VLDL. It is important to educate individuals on possible secondary causes of elevated lipid profiles. Proper management of the secondary causes provides a good prognosis for overall individual health.
Familial hypertriglyceridemia
Familial hypercholesterolemia
Combined hyperlipidemia
Lipoatrophic diabetes
Familial dysbetalipoproteinemia
Abetalipoproteinemia
Citrullinemia type I
HIDEA syndrome